It is characterized by the absence of ER, PR, and HER2 expression, coupled with elevated Ki-67 levels, leading to rapid growth, high recurrence rates, metastatic potential, worse prognosis, and limited treatment options than other BC subtypes (4, 5) (4, 6). The gene discussed is ERBB2; the disease is breast cancer.